# Altered PAPP-A and Placental Thickness in Pre-Eclampsia and Intrauterine Growth Restriction: A Pilot Study

**Authors:** Liviu Moraru, Raluca Moraru, Melinda Ildiko Mitranovici, Romeo Micu

PMC · DOI: 10.3390/jcm15041607 · 2026-02-19

## TL;DR

This study explores how first-trimester PAPP-A levels and placental thickness can predict pre-eclampsia and intrauterine growth restriction.

## Contribution

The study introduces a potential early screening method for pre-eclampsia and IUGR using PAPP-A levels and placental thickness.

## Key findings

- Low PAPP-A levels in the first trimester correlate with pre-eclampsia and IUGR.
- Placental thickness in the second trimester shows significant differences between groups.
- A PAPP-A cut-off of 0.65 MoM provides high sensitivity and specificity for predicting pre-eclampsia.

## Abstract

Pre-eclampsia (PE) is a multisystem disorder that affects 5–6% of all pregnancies. Background: PE and intrauterine growth restriction (IUGR) are two major causes of maternal mortality and morbidity. We hypothesize that first-trimester pregnancy-associated plasma protein-A (PAPP-A) levels are useful as a prognostic marker. The aim of our study is to identify the role of PAPP-A and placental thickness in pre-eclampsia screening, as well as its value in IUGR prognosis. Methods: This prospective study was conducted at the Al. Simionescu County Hospital Hunedoara, Romania, Department of Obstetrics and Gynecology, from 12 May to 31 October 2025. A total of 102 patients were included in our study; of these, 28 patients (28.56%) developed pre-eclampsia, and 13 (13.26%) developed IUGR associated with PE. Results: The demographic data showed no differences between groups, except for BMI, smoking habits, and diabetes mellitus. Of the 28 cases of pre-eclampsia, 14.28% had PE detected by 28 weeks, 46.4% had PE associated with IUGR by 33/34 weeks, and 39.32% had PE detected at term/delivery. The highest detection rate was at 33/34 weeks, when the association with IUGR was obvious. For PE with IUGR at 34 weeks, the area under the curve (AUC) was 0.909, with a p-value < 0.001. The PAPP-A cut-off was 0.65 MoM, indicating high sensitivity and specificity for predicting PE. Placental thickness was also assessed, resulting in statistically significant differences between groups. The PAPP-A level shows strong predictive value for PE, especially when associated with placental thickness. Conclusions: This study demonstrates a clear correlation between low PAPP-A in the first trimester of pregnancy, placental thickness in the second trimester, and the subsequent development of pre-eclampsia and its association with IUGR.

## Linked entities

- **Proteins:** PAPPA (pappalysin 1)
- **Diseases:** pre-eclampsia (MONDO:0005081), intrauterine growth restriction (MONDO:0005030), diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** PAPPA (pappalysin 1) [NCBI Gene 5069] {aka ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, LGALS13 (galectin 13) [NCBI Gene 29124] {aka GAL13, PLAC8, PP13}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, PIGF (phosphatidylinositol glycan anchor biosynthesis class F) [NCBI Gene 5281] {aka OORS}
- **Diseases:** chromosome abnormality (MESH:D002869), diabetes mellitus (MESH:D003920), PE (MESH:D011225), IUGR (MESH:D005317), congenital anomalies (MESH:D000013), inflammation (MESH:D007249), oligohydramnios (MESH:D016104), injury to (MESH:D014947), proteinuria (MESH:D011507), genetic abnormalities (MESH:D030342), abruptio placentae (MESH:D000037), hypoxia (MESH:D000860), gestational diabetes (MESH:D016640), HELLP syndrome (MESH:D017359), Eclampsia (MESH:D004461), placental dysfunction (MESH:D010922), gestational hypertension (MESH:D046110), infections (MESH:D007239), preterm delivery (MESH:D047928), premature rupture of membranes (MESH:D005322), thrombosis (MESH:D013927), PT (MESH:D006526), placental insufficiency (MESH:D010927), hypertension (MESH:D006973), Restriction (MESH:D002313), preterm labor (MESH:D007752), MoM (MESH:D020423), chronic diseases (MESH:D002908), renal disease (MESH:D007674), stillbirth (MESH:D050497), dysfunction (MESH:D006331)
- **Chemicals:** alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942390/full.md

---
Source: https://tomesphere.com/paper/PMC12942390